39
Participants
Start Date
February 28, 2007
Primary Completion Date
April 30, 2014
Study Completion Date
September 30, 2015
Enoxaparine
"Patients considered eligible will be divided into 2 groups- those receiving vasopressor support and those not receiving vasopressor support at the time of inclusion. The patients in each group will be randomized to receive enoxaparin in accordance with one of the following DVT prophylaxis protocols:~1. Intravenous Enoxaparine according to their weight (0.5mg/kg x 1/day)~2. Subcutaneous Enoxaparine according to their weight (0.5mg/kg x 1/day)~3. Subcutaneous Enoxaparine 40mg x1/day"
Shaare Zedek Medical Center, Jerusalem
Shaare Zedek Medical Center
OTHER